AMEI's Current Trends in Diagnosis & Treatment

Register      Login

VOLUME 4 , ISSUE 2 ( July-December, 2020 ) > List of Articles


Off-label Prescription and Challenges in Clinical Practice: An Abridged Review

Deepika Tikoo

Citation Information : Tikoo D. Off-label Prescription and Challenges in Clinical Practice: An Abridged Review. Curr Trends Diagn Treat 2020; 4 (2):87-90.

DOI: 10.5005/jp-journals-10055-0098

License: CC BY-NC 4.0

Published Online: 01-12-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Off-label use of drugs means the use of drugs for indications, dose, dosage forms, route, and patient population for which approval from the regulatory bodies like US Food and Drug Administration (US FDA) and Drugs Controller General of India (DCGI) has not been obtained. It does not mean that it is illegal or contraindicated to use the drug as off-label. The purpose of off-label prescribing is to provide the maximum benefit to the patients, especially the vulnerable population like pediatric, psychiatric, pregnant, and cancer patients where there is not sufficient data available for the drug use or in diseases where no treatment is yet available. Hence, valid scientific data and an expert opinion can be relied upon for off-label use. There still remains concerns for safety when prescribing for off-label purpose due to the lack of adequate safety and efficacy studies, and thus a physician must assess the risk/benefit ratio before its use. The regulatory bodies like US FDA has formulated certain guidelines for off-label use while the DCGI still does not support its use. Hence, there is no uniformity in the rules and regulations about off-label prescribing around the world, which needs to be streamlined.

  1. Oberoi SS. Regulating off-label drug use in India: the arena for concern. Perspect Clin Res 2015 Jul–Sep;6(3):129–133. DOI: 10.4103/2229-3485.159935.
  2. Khamar B. Off-label use of medicines: medical research and medical practice. Indian J Ophthalmol 2007;55(6):411–412. DOI: 10.4103/0301-4738.36472.
  3. Lücke C, Gschossmann JM, Grömer TW, et al. Off-label prescription of psychiatric drugs by non psychiatrist physicians in three general hospitals in Germany. Ann Gen Psychiatry 2018 Feb;17:1–7. DOI: 10.1186/s12991-018-0176-4.
  4. Shakeel S, Iffat W, Nesar S, et al. Exploratory findings of prescribing unlicensed and of label medicines among children and neonates. Integr Pharm Res Pract 2020;9:33–39. DOI: 10.2147/IPRP.S231134.
  5. Mukattash TL, Alzoubi KH, Abuirjie AM, et al. Perceptions and attitudes towards off-label dispensing for pediatric patients, a study of hospital based pharmacists in Jordan. Saudi Pharm J 2018 Jan;26(1):20–24. DOI: 10.1016/j.jsps.2017.11.004.
  6. McIntyre J, Conroy S, Avery A, et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000;83(6):498–501. DOI: 10.1136/adc.83.6.498.
  7. Sophie H, McNair DS, Birkett NJ, et al. Off-label use of cancer therapies in women diagnosed with breast cancer in the United States. SpringerPlus 2015 May;4:209. DOI: 10.1186/s40064-015-0981-z.
  8. Shimazawa R, Ikeda M. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications. Clin Ther 2012;34(10):2104–2116. DOI: 10.1016/j.clinthera.2012.09.004.
  9. Council of Australian Therapeutic Advisory Groups (CATAG). Rethinking medicines decision-making in Australian Hospitals: Guiding principles for the quality of off-label medicines. Accessed 09 Jul 2020.
  10. Gupta SK, Nayak RP. Off label use of medicine: perspective of physicians, patients, pharmaceutical companies and regulatory authorities. J Pharmacol Pharmacother. 2014 Apr–Jun;5(2):88–92. DOI: 10.4103/0976-500X.130046.
  11. Berman AF, Melnick D. Off-label promotion, on-target sales. PLoS Med 2008;5(10):e210. DOI: 10.1371/journal.pmed.0050210. PMCID: PMC2573913; PubMed: 18959472.
  12. Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics 2009;37(3):476–486, 396. DOI: 10.1111/j.1748-720X.2009.00408.x. PMCID: PMC2836889; PubMed: 19723258.
  13. Committee on Drugs. Off-label use of drugs in children. Pediatrics 2014 Mar;133(3):563–567. DOI: 10.1542/peds.2013-4060.
  14. Furey K, Wilkins K. Prescribing “off-label”: what should a physician disclose? AMA J Ethics. 2016 Jun:18(6):587–593. DOI: 10.1001/journalofethics.2016.18.6.ecas3-1606.
  15. Carneiro AV, Costa J. Off-label prescription: practice and problems. Rev Port Cardiol 2013 Sep;32(9):681–686. DOI: 10.1016/j.repc.2013.01.006. Epub 2013 Jul 27.
  16. Peckham AM, Evoy KE3, Ochs L, Covvey JR. Gabapentin for off-label use: evidence-based or cause for concern? Subst Abuse 2018;12:1178221818801311. DOI: 10.1177/1178221818801311.
  17. Kharod SC, Kang SK, Kadam SD. Off-label use of Bumetanide for brain disorders: an overview. Front Neurosci 2019 Apr;13:310. DOI: 10.3389/fnins.2019.00310.
  18. Stoehr JR, Choi JN, Colavincenzo M, et al. Off-label use of topical Minoxidil in Alopecia: a review. Am J Clin Dermatol 2019 Apr;20(2):237–250. DOI: 10.1007/s40257-018-0409-y.
  19. Oliphant CS, Owens RE, Bolorunduro OB, et al. Ivabradine: a review of labeled and off-label uses. Am J Cardiovasc Drugs. 2016 Jul;16:337–347. DOI: 10.1007/s40256-016-0178-z.
  20. O'Shae T. 10 surprising off-label uses for prescription medications. Accessed from
  21. Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA 2020 May;323(19):1897–1898. DOI: 10.1001/jama.2020.4742.
  22. Shojaei A, Salari P. COVID-19 and off label use of drugs: an ethical viewpoint. Daru 2020 Dec;28(2):789–793. DOI: 10.1007/s40199-020-00351-y. Epub 2020 May 8. PMID: 32385829; PMCID: PMC7207985.
  23. Miller K. Off label drug use: what you need to know. Available from:
  24. Lenk C, Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag 2014 Jul 12;10:537–546. DOI: 10.2147/TCRM.S40232. PMID: 25050064; PMCID: PMC4103928.
  25. Day R. Off-label prescribing. Aust Prescr 2013;36:182–183.
  26. Field RI. The FDA's new guidance for off-label promotion is only a start. P&T 2008 Apr;33(4):220–249.
  27. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166(9):1021–1026. DOI: 10.1001/archinte.166.9.1021.
  28. Mudur G. Indian Medical Association wants off label prescribing. BMJ 2004 Apr;328(7446):974. DOI: 10.1136/bmj.328.7446.974-c.
  29. Gota V, Divatia JV. Off label use of drugs: an evil or a necessity? Indian J Anaesth 2015 Dec;59(12):767–768. DOI: 10.4103/0019-5049.171555.
  30. Yackey K, Stukus K, Cohen D, et al. Off-label medication prescribing patterns in pediatrics: an update. Hosp Pediatr 2019 Mar;9(3);186–193. DOI: 10.1542/hpeds.2018-0168.
  31. Weda M, Hoebert J, Vervloet M, et al. Study on off-label use of medicinal products in the European Union. Accessed on July 9, 2020.
  32. Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther 2017;42(3):251–258. DOI: 10.1111/jcpt.12507.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.